295 related articles for article (PubMed ID: 29734483)
1. Role of dynamic contrast-enhanced MRI in evaluating the association between contralateral parenchymal enhancement and survival outcome in ER-positive, HER2-negative, node-negative invasive breast cancer.
Shin GW; Zhang Y; Kim MJ; Su MY; Kim EK; Moon HJ; Yoon JH; Park VY
J Magn Reson Imaging; 2018 Dec; 48(6):1678-1689. PubMed ID: 29734483
[TBL] [Abstract][Full Text] [Related]
2. Background Parenchymal Enhancement on Preoperative Magnetic Resonance Imaging: Association With Recurrence-Free Survival in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
Choi JS; Ko ES; Ko EY; Han BK; Nam SJ
Medicine (Baltimore); 2016 Mar; 95(9):e3000. PubMed ID: 26945421
[TBL] [Abstract][Full Text] [Related]
3. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
Lim Y; Ko ES; Han BK; Ko EY; Choi JS; Lee JE; Lee SK
Breast Cancer Res Treat; 2017 Jun; 163(3):573-586. PubMed ID: 28349273
[TBL] [Abstract][Full Text] [Related]
4. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
5. Contralateral parenchymal enhancement on dynamic contrast-enhanced MRI reproduces as a biomarker of survival in ER-positive/HER2-negative breast cancer patients.
van der Velden BHM; Sutton EJ; Carbonaro LA; Pijnappel RM; Morris EA; Gilhuijs KGA
Eur Radiol; 2018 Nov; 28(11):4705-4716. PubMed ID: 29736850
[TBL] [Abstract][Full Text] [Related]
6. Association between contralateral background parenchymal enhancement on MRI and outcome in patients with unilateral invasive breast cancer receiving neoadjuvant chemotherapy.
Rella R; Bufi E; Belli P; Scrofani AR; Petta F; Borghetti A; Marazzi F; Valentini V; Manfredi R
Diagn Interv Imaging; 2022 Oct; 103(10):486-494. PubMed ID: 35585020
[TBL] [Abstract][Full Text] [Related]
7. Enhancement parameters on dynamic contrast enhanced breast MRI: do they correlate with prognostic factors and subtypes of breast cancers?
Kim JY; Kim SH; Kim YJ; Kang BJ; An YY; Lee AW; Song BJ; Park YS; Lee HB
Magn Reson Imaging; 2015 Jan; 33(1):72-80. PubMed ID: 25179138
[TBL] [Abstract][Full Text] [Related]
8. Long-term Survival in Breast Cancer Patients Is Associated with Contralateral Parenchymal Enhancement at MRI: Outcomes of the SELECT Study.
Ragusi MAA; van der Velden BHM; Meeuwis C; Tetteroo E; Coerkamp EG; van Nijnatten TJA; Jansen FH; Wolters-van der Ben EJM; Jongen L; van Raamt F; Dorrius MD; Verloop J; Viergever MA; Pijnappel RM; Elias SG; Gilhuijs KGA
Radiology; 2023 May; 307(4):e221922. PubMed ID: 36975820
[TBL] [Abstract][Full Text] [Related]
9. Background parenchymal enhancement on breast MRI and mammographic breast density: correlation with tumour characteristics.
Kim MY; Choi N; Yang JH; Yoo YB; Park KS
Clin Radiol; 2015 Jul; 70(7):706-10. PubMed ID: 25824280
[TBL] [Abstract][Full Text] [Related]
10. DCE-MRI texture analysis with tumor subregion partitioning for predicting Ki-67 status of estrogen receptor-positive breast cancers.
Fan M; Cheng H; Zhang P; Gao X; Zhang J; Shao G; Li L
J Magn Reson Imaging; 2018 Jul; 48(1):237-247. PubMed ID: 29219225
[TBL] [Abstract][Full Text] [Related]
11. Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER
van der Velden BHM; Elias SG; Bismeijer T; Loo CE; Viergever MA; Wessels LFA; Gilhuijs KGA
Clin Cancer Res; 2017 Nov; 23(21):6505-6515. PubMed ID: 28790119
[No Abstract] [Full Text] [Related]
12. Quantitative background parenchymal enhancement to predict recurrence after neoadjuvant chemotherapy for breast cancer.
Moliere S; Oddou I; Noblet V; Veillon F; Mathelin C
Sci Rep; 2019 Dec; 9(1):19185. PubMed ID: 31844135
[TBL] [Abstract][Full Text] [Related]
13. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
[TBL] [Abstract][Full Text] [Related]
14. Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?
van der Velden BHM; Bismeijer T; Canisius S; Loo CE; Lips EH; Wesseling J; Viergever MA; Wessels LFA; Gilhuijs KGA
Eur J Radiol; 2019 Dec; 121():108705. PubMed ID: 31655316
[TBL] [Abstract][Full Text] [Related]
15. Fully Automatic Assessment of Background Parenchymal Enhancement on Breast MRI Using Machine-Learning Models.
Nam Y; Park GE; Kang J; Kim SH
J Magn Reson Imaging; 2021 Mar; 53(3):818-826. PubMed ID: 33219624
[TBL] [Abstract][Full Text] [Related]
16. Comparison between qualitative and quantitative assessment of background parenchymal enhancement on breast MRI.
Pujara AC; Mikheev A; Rusinek H; Gao Y; Chhor C; Pysarenko K; Rallapalli H; Walczyk J; Moccaldi M; Babb JS; Melsaether AN
J Magn Reson Imaging; 2018 Jun; 47(6):1685-1691. PubMed ID: 29140576
[TBL] [Abstract][Full Text] [Related]
17. Time-to-enhancement at ultrafast breast DCE-MRI: potential imaging biomarker of tumour aggressiveness.
Shin SU; Cho N; Kim SY; Lee SH; Chang JM; Moon WK
Eur Radiol; 2020 Jul; 30(7):4058-4068. PubMed ID: 32144456
[TBL] [Abstract][Full Text] [Related]
18. Machine learning-based prediction of future breast cancer using algorithmically measured background parenchymal enhancement on high-risk screening MRI.
Saha A; Grimm LJ; Ghate SV; Kim CE; Soo MS; Yoon SC; Mazurowski MA
J Magn Reson Imaging; 2019 Aug; 50(2):456-464. PubMed ID: 30648316
[TBL] [Abstract][Full Text] [Related]
19. The correlation of background parenchymal enhancement in the contralateral breast with patient and tumor characteristics of MRI-screen detected breast cancers.
Vreemann S; Gubern-Mérida A; Borelli C; Bult P; Karssemeijer N; Mann RM
PLoS One; 2018; 13(1):e0191399. PubMed ID: 29351560
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Breast Cancer Morphology Using Diffusion-Weighted and Dynamic Contrast-Enhanced MRI: Intermethod and Interobserver Agreement.
Radovic N; Ivanac G; Divjak E; Biondic I; Bulum A; Brkljacic B
J Magn Reson Imaging; 2019 May; 49(5):1381-1390. PubMed ID: 30325549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
